Saturday, August 27, 2016

Roth starts Actinium Pharma at buy

Roth starts Actinium Pharma at buy

August 25, 2016 by · Leave a Comment 

Tweet Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data […]

Roth ups CymaBay price target to $6

Roth ups CymaBay price target to $6

August 12, 2016 by · Leave a Comment 

Tweet Roth Capital Partners raised its price target for CymaBay Therapeutics (NASDAQ:CBAY) to $6 from $4, citing a potential partnership for the company’s gout product. The stock closed at $1.79 on Thursday. “Following conversations with management, we are more confident that CymaBay could ink a partnership for arhalofenate (gout) in the coming six-to-12 months,” writes […]

Roth reinitiates coverage of Pieris Pharma at buy

Roth reinitiates coverage of Pieris Pharma at buy

August 5, 2016 by · Leave a Comment 

Tweet Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday. “We believe the company’s anticalin platform has broad potential for the long term and that the multiple partners, broad pipeline and flexibility of the platform provide investors with the potential […]

Roth downgrades TearLab to neutral

Roth downgrades TearLab to neutral

August 4, 2016 by · Leave a Comment 

Tweet Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday. Analyst Chris Lewis writes that TearLab’s second quarter year-over-year growth of 9% was the lowest since the first quarter of 2012, prompting the company to once again lower its 2016 outlook. […]

Roth cuts GenVec price target to $2

Roth cuts GenVec price target to $2

July 25, 2016 by · Leave a Comment 

Tweet Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60 cents on Friday. “This is an important milestone for the GenVec as CGF166 could be the first gene […]

Roth resumes coverage of CymaBay

Roth resumes coverage of CymaBay

July 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday. “In our opinion, while catalysts for the next 12-to-18 months are limited, the potential partnering of arhalofenate could be a significant driver for the shares, enhancing CymaBay’s coffers, validating […]

Roth resumes coverage of Galectin Therapeutics

Roth resumes coverage of Galectin Therapeutics

July 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners resumed coverage of Galectin Therapeutics (NASDAQ:GALT) with a “buy” rating and $3 price target. The stock closed at $1.52 on Friday. “In our opinion, Phase 1 data demonstrated Galectin’s GR-MD-02’s positive effect on NASH fibrosis biomarkers,” writes analyst Sa’ar Yaniv. “While we are expect that the 30-patient placebo-controlled Phase 2 study […]

Roth starts Heat Biologics at buy

Roth starts Heat Biologics at buy

June 20, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $2.75 price target. The stock closed at 60 cents on Friday. “Heat Biologics possesses a portfolio of unique, differentiated vaccines that, in our opinion, could bring a much needed boost to the cancer vaccine space, which has been plagued […]

Roth starts PhaseRx at buy

Roth starts PhaseRx at buy

June 17, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday. “In our opinion, PhaseRx’s technology platform, combined with promising preclinical results, first mover advantage in the multi-billion dollar i-ERT market opportunity, a number of potential upcoming milestones, and […]

Roth starts Capricor Therapeutics at buy

Roth starts Capricor Therapeutics at buy

June 15, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of Capricor Therapeutics (NASDAQ:CAPR) with a “buy” rating and $12 price target. The stock closed at $4.17, up 63 cents, on Wednesday. “We believe Capricor is a stem cell player poised for a major leadership role in the treatment of cardiovascular disease,” writes analyst Joseph Pantginis. “Supporting this […]

Next Page »

Email Newsletters with Constant Contact
Google+